Audit: QRS - Echinacea for Health & Longevity
Audit conducted on 18/07/2026 02:27 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 84 |
| Failed | 0 |
| N/A | 7 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All content traces to the ER: protocol doses (ER §Therapeutic Protocol), gates (ER §Key Interactions & Contraindications), benefits/risks tiers, monitoring markers, and qualitative items all match. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious framing preserved (e.g., “theoretical liver stress”, “results are mixed and uncertain”). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening/softening; pregnancy retained under Contraindications consistent with ER “avoid or use caution” population. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications and interactions both drawn from the ER §Key Interactions & Contraindications; no modifying factors misclassified. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs, expert names, or brands introduced in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No new attributions present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Neutral, objective tone consistent with the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Meets tone requirement. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents information without prescriptive instruction. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Content is descriptive; footer disclaimer is fixed template text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No recommending/advising language in content spans. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address in content. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; technical terms only where they mirror ER labels. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact cells and bullets throughout. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address in content spans. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing suits the target audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol detail (split dosing, monitoring) reflects this audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not framed for the general population. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance and tiers reflect a proactive, longevity-oriented reading. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. | 🟢 | Uses “Health & Longevity”; no “anti-aging” phrasing. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. | 🟢 | Formal register; “stomach upset” mirrors ER wording (ER §Protocol/§Risk Mitigation). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: card/section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); gate headings (“Contraindications”, “Key Interactions”); tier labels (“High”, “Medium”, “Low”, “Speculative”); Monitoring column headers (“Marker”, “Target”, “Why”). | 🟢 | All fixed labels/headings present and unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template variable spans present, including the hidden empty-state ones. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Unaddressed spans left intact. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty in a way that requires empty-state phrasing; absent tiers are hidden per 12.5/13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Monitoring markers and gate items use ER-sourced labels; interaction gate labels identify the interacting agent per §9. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented labels. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators in content; tiers conveyed via bold labels and CSS. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed to fit a single sheet. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is first element (lines 2-14). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by — / — inside the comment. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; duration “00:04” quoted (contains colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: echinacea_2026-0718-0117_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 matches prompt version. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” | 🟢 | qrs_creation_date: 2026-0718-0219 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. | 🟢 | “Opus” is a single word. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 4.8 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier | 🟢 | “Opus 4.8” = nickname + version. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: echinacea_2026-0718-0117_Opus_QRS.html |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed and correctly quoted. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. | 🟢 | “Echinacea for Health & Longevity - Quick Reference Sheet” with & encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. | 🟢 | “Echinacea for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0718 → 07/18/2026. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 4.8”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only title and required subline; no AKA line, badge, or audit date. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Distills the ER Conclusion (line 395): immune support, modest cold benefit, tolerability, quality caveat. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each claim maps to the Conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or specialist terms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial citations. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes or statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER “Populations who should avoid or use caution” bullet (line 274). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six populations represented. |
| 8.3 | Individual [stop_items] are formatted as <li></li> |
🟢 | Each item is an <li>. |
| 8.4 | Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, study details, or content after em-/en-/hyphen-dash. Just the key fact. | 🟢 | Rationale stripped (e.g., “(rash and hypersensitivity risk)”, “— a traditional caution” removed). |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved, kept as concise as possible. | 🟢 | Disease examples and age windows preserved (autoimmune diseases, TB/HIV, under 2 / under 12). |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list. | N/A | The ER contraindication bullet uses no ranking notation. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Stop items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from the ER interaction bullets (lines 262-268). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Immunosuppressants (a contraindication) correctly excluded. |
| 9.3 | Individual [caution_items] are formatted as <li></li> |
🟢 | Each item is an <li>. |
| 9.4 | Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, study details, or content after em-/en-/hyphen-dash. Just the key fact. | 🟢 | Mechanistic rationale stripped; only agent + examples retained. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved, kept as concise as possible. | 🟢 | Example drugs preserved (midazolam/simvastatin; caffeine/theophylline/clozapine; astragalus/andrographis/elderberry). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list. | N/A | The ER interaction bullets use no ranking notation. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Caution items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Doses and schedule sourced from the ER §Therapeutic Protocol (lines 296-306). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Acute treatment, seasonal prevention, dosing schedule. |
| 10.3 | If less than three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct actionable aspects are present and used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All three action sets populated with ER-derived content. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | ER supplies two aspects (acute, prevention); both captured. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Acute use ordered before prevention. |
| 11.3 | If less than three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | 🟢 | Only two aspects exist; time_3 set to display:none and empty. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Both used time sets are populated from ER §Practical Considerations (line 340). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Tiers mirror the ER §Expected Benefits. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four variables handled. |
| 12.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. Just the key fact. | 🟢 | Only benefit headings retained; conflicted flags and magnitudes stripped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheticals carried through (e.g., “(Anxiety-Reducing)” dropped). |
| 12.5 | If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. | 🟢 | ER has no High benefits; benefits_high set to display:none. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Tiers mirror the ER §Potential Risks & Side Effects. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four variables handled. |
| 13.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. Just the key fact. | 🟢 | Only risk headings retained. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheticals carried through. |
| 13.5 | If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. | 🟢 | ER has no High risks; risks_high set to display:none. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Markers and cadence sourced from the ER §Monitoring Protocol (lines 360-369). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All four biomarkers listed: WBC w/ differential, Eosinophils, ALT & AST, hs-CRP. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence populated from ER lines 360-362. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Sourced from the ER qualitative-marker list (lines 373-377). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five qualitative markers listed verbatim. |
Issues 18/07/2026 02:27
Pass rate 100.00%. No issues found.